Multi Vessel Coronary Artery DiseaseMPR-CADNCT07866404
Medical Management vs Partial Revascularization in Diffuse Multivessel Coronary Artery Disease
A study testing Partial per cutaneous coronary intervention and Optimal medical therapy (OMT) in people with Multi Vessel Coronary Artery Disease, run by CH. Pervaiz Elahi Institute of Cardiology, Multan at 1 site in Pakistan.
Trial summary
This randomized controlled trial will compare the clinical outcomes of partial revascularization with percutaneous coronary intervention (PCI) versus optimal medical therapy (OMT) alone in patients with diffuse multivessel coronary artery disease who are not suitable for complete surgical or percutaneous… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multi Vessel Coronary Artery Disease
- What is being tested?
- Partial per cutaneous coronary intervention and Optimal medical therapy (OMT)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 140 participants
- Where
- 1 sitePakistan
- Study dates
- 16 Jul 2025to 15 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- Diffuse multivessel coronary artery disease confirmed by coronary angiography.
- Not suitable for complete percutaneous or surgical revascularization as determined by the Heart Team.
- PCI of the LAD is technically possible.
- No planned surgical revascularization.
- Willingness to provide informed consent.
Who cannot join
- Acute ST-segment elevation myocardial infarction requiring emergent PCI.
- Cardiogenic shock.
- Previous CABG.
- Significant valvular disease requiring surgery.
- Unwillingness to provide informed consent.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison of Clinical Outcome of Medical Management vs Partial Revascularization in Patients of Multivessel Diffuse Coronary Artery Disease Not Suitable for CABG: A Randomized Controlled Trial.
This randomized controlled trial will compare the clinical outcomes of partial revascularization with percutaneous coronary intervention (PCI) versus optimal medical therapy (OMT) alone in patients with diffuse multivessel coronary artery disease who are not suitable for complete surgical or percutaneous revascularization. A total of 140 eligible patients will be randomized into two groups. The partial revascularization group will undergo PCI of the left anterior descending artery, while the control group will receive guideline-directed optimal medical therapy. Patients will be followed for 12 months, with major adverse cardiovascular events (MACE) and Canadian Cardiovascular Society (CCS) angina class assessed at 3, 6, and 12 months.
Read the detailed description
This randomized controlled trial will compare the clinical outcomes of medical management versus partial revascularization in patients with angiographically confirmed diffuse multivessel coronary artery disease who are considered unsuitable for complete revascularization by coronary artery bypass grafting (CABG) or complete percutaneous coronary intervention (PCI), but in whom PCI of the left anterior descending (LAD) artery is technically feasible.
Eligible participants will be assessed by a Heart Team consisting at minimum of a cardiac surgeon and an interventional cardiologist. Participants will be randomly assigned to one of two parallel treatment groups. The partial revascularization group will undergo PCI of the LAD, while the medical management group will receive optimal medical therapy.
Participants will be followed for 12 months, with assessments at 3, 6, and 12 months. The primary outcome will be the occurrence of major adverse cardiovascular events (MACE) at 12 months, defined as cardiovascular death, nonfatal myocardial infarction, or urgent unplanned revascularization. Secondary outcomes will include angina severity according to the Canadian Cardiovascular Society (CCS) classification, MACE at earlier follow-up points, and hospitalization for acute coronary syndrome.
The study aims to determine whether partial revascularization of the LAD provides better clinical outcomes compared with medical management alone in this selected group of patients with diffuse multivessel coronary artery disease who are not suitable for complete revascularization.
- Conditions
- Multi Vessel Coronary Artery Disease
- Being tested
- Partial per cutaneous coronary intervention, Optimal medical therapy (OMT)
- Keywords
- ACS, CAD, MACE, OMT
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Partial per cutaneous coronary interventionProcedure or surgery
PCI of the left anterior descending artery in patients with diffuse multi vessel coronary artery disease who are not suitable for complete Revascularization
Optimal medical therapy (OMT)Drug
Patients managed conservatively with guideline directed medical therapy.
| Study group | Role | What they receive |
|---|---|---|
| Partial Revascularization | Experimental | Patients will undergo partial per cutaneous coronary intervention (PCI) of Left anterior descending artery (LAD) , without achieving complete anatomical Revascularization of all diseased coronary vessels. Receives: Procedure: Partial per cutaneous coronary intervention |
| Optimal medical therapy | Active comparator | Patients will receive guideline directed optimal medical therapy for coronary artery disease without planned per cutaneous intervention. Receives: Drug: Optimal medical therapy (OMT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Major adverse cardiovascular events (MACE)
Frequency of major adverse cardiovascular events, defined as the composite of cardiovascular death, non-fatal myocardial infarction, and urgent unplanned revascularization.
Measured: 12 months after randomization
Secondary outcomes (4)
Canadian Cardiovascular Society (CCS) Angina Class
Change in angina severity according to the Canadian Cardiovascular Society angina classification.
Measured: 3, 6, and 12 months after randomization
Major Adverse Cardiovascular Events at 3 Months
Frequency of MACE, defined as cardiovascular death, non-fatal myocardial infarction, or urgent unplanned revascularization.
Measured: 3 months
Major Adverse Cardiovascular Events at 6 Months
Frequency of MACE, defined as cardiovascular death, non-fatal myocardial infarction, or urgent unplanned revascularization.
Measured: 6 months
Hospitalization Due to Acute Coronary Syndrome
Frequency of hospital admission due to acute coronary syndrome during follow-up.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2026
- Study start16 Jul 2025
- Primary completion15 Jan 2027 (estimated)
- Study completion15 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multi Vessel Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 140 participants (estimated)
Sponsor and investigators
- Lead sponsor
- CH. Pervaiz Elahi Institute of Cardiology, Multan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Abdur Raheem, CH. Pervaiz Elahi Institute of Cardiology, Multan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07866404
- Sponsor's protocol ID
- 273
- Acronym
- MPR-CAD
- Status last verified
- Oct 2026
- First submitted
- 4 Oct 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be made available to other researchers.
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Clinical Outcome of Medical Management vs Partial Revascularization in Patients of Multivessel Diffuse Coronary Artery Disease Not Suitable for CABG: A Randomized Controlled Trial.
- ClinicalTrials.gov ID
- NCT07866404
- Acronym / sponsor ID
- MPR-CAD / 273
- Conditions
- Multi Vessel Coronary Artery Disease
- Keywords
- ACS, CAD, MACE, OMT
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 140 participants (estimated)
- Lead sponsor
- CH. Pervaiz Elahi Institute of Cardiology, MultanUniversity, hospital or other
- Study start
- 16 Jul 2025 (actual)
- Primary completion
- 15 Jan 2027 (estimated)
- Study completion
- 15 Jan 2027 (estimated)
- First posted
- 8 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled trial will compare the clinical outcomes of partial revascularization with percutaneous coronary intervention (PCI) versus optimal medical therapy (OMT) alone in patients with diffuse multivessel coronary artery disease who are not suitable for complete surgical or percutaneous revascularization. A total of 140 eligible patients will be randomized into two groups. The partial revascularization group will undergo PCI of the left anterior descending artery, while the control group will receive guideline-directed optimal medical therapy. Patients will be followed for 12 months, with major adverse cardiovascular events (MACE) and Canadian Cardiovascular Society (CCS) angina class assessed at 3, 6, and 12 months.
Detailed description
This randomized controlled trial will compare the clinical outcomes of medical management versus partial revascularization in patients with angiographically confirmed diffuse multivessel coronary artery disease who are considered unsuitable for complete revascularization by coronary artery bypass grafting (CABG) or complete percutaneous coronary intervention (PCI), but in whom PCI of the left anterior descending (LAD) artery is technically feasible.
Eligible participants will be assessed by a Heart Team consisting at minimum of a cardiac surgeon and an interventional cardiologist. Participants will be randomly assigned to one of two parallel treatment groups. The partial revascularization group will undergo PCI of the LAD, while the medical management group will receive optimal medical therapy.
Participants will be followed for 12 months, with assessments at 3, 6, and 12 months. The primary outcome will be the occurrence of major adverse cardiovascular events (MACE) at 12 months, defined as cardiovascular death, nonfatal myocardial infarction, or urgent unplanned revascularization. Secondary outcomes will include angina severity according to the Canadian Cardiovascular Society (CCS) classification, MACE at earlier follow-up points, and hospitalization for acute coronary syndrome.
The study aims to determine whether partial revascularization of the LAD provides better clinical outcomes compared with medical management alone in this selected group of patients with diffuse multivessel coronary artery disease who are not suitable for complete revascularization.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Partial Revascularization | Experimental | Procedure: Partial per cutaneous coronary interventionPatients will undergo partial per cutaneous coronary intervention (PCI) of Left anterior descending artery (LAD) , without achieving complete anatomical Revascularization of all diseased coronary vessels. |
| Optimal medical therapy | Active comparator | Drug: Optimal medical therapy (OMT)Patients will receive guideline directed optimal medical therapy for coronary artery disease without planned per cutaneous intervention. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age ≥18 years
- Diffuse multivessel coronary artery disease confirmed by coronary angiography.
- Not suitable for complete percutaneous or surgical revascularization as determined by the Heart Team.
- PCI of the LAD is technically possible.
- No planned surgical revascularization.
Key exclusion criteria (5 listed)
- Acute ST-segment elevation myocardial infarction requiring emergent PCI.
- Cardiogenic shock.
- Previous CABG.
- Significant valvular disease requiring surgery.
- Unwillingness to provide informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Partial per cutaneous coronary interventionPCI of the left anterior descending artery in patients with diffuse multi vessel coronary artery disease who are not suitable for complete Revascularization | Procedure or surgery | Partial Revascularization |
| Optimal medical therapy (OMT)Patients managed conservatively with guideline directed medical therapy. | Drug | Optimal medical therapy |
Primary outcome
Major adverse cardiovascular events (MACE)
Time frame: 12 months after randomization
Frequency of major adverse cardiovascular events, defined as the composite of cardiovascular death, non-fatal myocardial infarction, and urgent unplanned revascularization.
4 secondary outcomes
Canadian Cardiovascular Society (CCS) Angina Class
Time frame: 3, 6, and 12 months after randomization
Major Adverse Cardiovascular Events at 3 Months
Time frame: 3 months
Major Adverse Cardiovascular Events at 6 Months
Time frame: 6 months
Hospitalization Due to Acute Coronary Syndrome
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be made available to other researchers.
Related trials for Multi Vessel Coronary Artery Disease
Recruiting
Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD
Multi Vessel Coronary Artery Disease, Percutaneous Coronary Intervention
Active, not recruiting
iFR Guided Multi-vessel Revascularization During Percutaneous Coronary Intervention for Acute Myocardial Infarction
Acute Myocardial Infarction, Multi Vessel Coronary Artery Disease
Enrolling by invitation
Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH)
Multi Vessel Coronary Artery Disease
Enrolling by invitation
Safety Study of Acellular Tissue Engineered Vessel for Coronary Artery Bypass
Coronary Artery Disease, Multi Vessel Coronary Artery Disease
Recruiting
Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)
Myocardial Infarction, Acute, Multi-Vessel Coronary Artery Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Partial per cutaneous coronary intervention and Optimal medical therapy (OMT) in people with Multi Vessel Coronary Artery Disease, run by CH. Pervaiz Elahi Institute of Cardiology, Multan at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Major adverse cardiovascular events (MACE) (time frame: 12 months after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026; AzTrials last refreshed its copy on 30 Oct 2026.